Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.
|Articles|September 16, 2008
- April15 2003
- Volume 10
- Issue 7
THE 50% CREDIT FLAG
Author(s)Michael Sheehan
Advertisement
Most lenders get leery when theysee credit card accounts or homeequity loans on your credit reportwith balances that are more than50% of the account limit. To avoidgetting tagged as a poorer credit riskthan you really are, ask your cardissuer to raise the limit on theaccount. If that doesn't work, thinkabout putting part of the debt onanother card. Be careful with the latteroption, though; lenders also don'tlike to see a lot of new applicationsfor credit cards on your report andwill downgrade you as a credit risk ifthey see too many.
Articles in this issue
about 18 years ago
Secure Tomorrow, Don't Lose Todayabout 18 years ago
Avoid the Turmoil of Insurance Mistakesabout 18 years ago
Bulletproof Your Car from the IRS' Aimabout 18 years ago
The PMD Answerman Q & Aabout 18 years ago
Impart Financial Values to Your Childrenabout 18 years ago
Watch Your Nest Egg's Financial Healthabout 18 years ago
Invest Some Land in Your 401(k) Accountabout 18 years ago
Plan According to Social Security Rulesabout 18 years ago
Discover Another Defined-Benefit Avenueabout 18 years ago
Know All Your Estate Planning BenefitsAdvertisement
Related to this article
Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.
Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.
A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.
A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations
2
Hidradenitis Suppurativa Care: Expectations, Comorbidities, and Wound Care
3
Finerenone Outperforms Spironolactone, Eplerenone in HFpEF, HFmrEF Renal Outcomes
4
Why Early Advanced Therapy Matters in Hidradenitis Suppurativa
5